For an adult patient with differentiated thyroid carcinoma requiring postoperative external-beam radiotherapy, what are the recommended guidelines for contouring the clinical target volume of the thyroidectomy bed and elective neck nodal levels?

Radiotherapy Contouring Guidelines for Differentiated Thyroid Cancer

Clinical Target Volume for Thyroidectomy Bed

For differentiated thyroid carcinoma requiring postoperative external-beam radiotherapy, the clinical target volume should include the thyroid bed and regional neck nodes extending from the tips of the mastoid processes or hyoid down to the carina, with lateral extension to include both sides of the neck and supraclavicular fossae, while the superior mediastinum (level VII) should be included but excluding the lymph nodes within the anterior and posterior mediastinum extending from the brachiocephalic veins to the carina (compartment 4). 1, 2

Thyroid Bed Contouring Principles

• The thyroid bed encompasses the entire thyroidectomy site with appropriate margins based on surgical pathology and extent of disease 1
• Surgical clips are valuable for defining areas of likely residual disease and should be used to guide boost volumes when available 3
• The superior border extends from the tips of the mastoid processes or hyoid bone, depending on the extent of disease 2
• The inferior border extends down to the carina to adequately cover the superior mediastinum 1, 2

Critical Anatomic Boundaries

• Lateral borders include both sides of the neck and supraclavicular fossae to encompass the regional nodal drainage 2
• The mandible and infraclavicular portions of both lungs should be shielded to minimize toxicity 2
• No midline lead shielding should be used in the phase one volume to ensure adequate coverage of central structures 2

Elective Neck Node Contouring

Superior Mediastinum Inclusion

The superior mediastinum (level VII) must be included in the clinical target volume, as this is a common site of recurrence in differentiated thyroid cancer 1. However, the lymph nodes within the anterior and posterior mediastinum extending from the brachiocephalic veins to the carina (compartment 4) should be excluded from the elective volume 1.

This recommendation is based on a key study demonstrating that:

• All mediastinal recurrences occurred in the superior mediastinum (level VII) 1
• Mediastinal recurrences did not occur in isolation but were accompanied by neck recurrences 1
• Excluding compartment 4 facilitates dose escalation while avoiding radiation-induced mediastinal toxicity 1

Elective Field vs. Limited Field Approach

An elective field approach that includes the primary tumor bed and regional nodal areas in the cervical neck and upper mediastinum provides significantly better locoregional control compared to limited field radiotherapy (5-year locoregional control: 89% vs. 40%, p = 0.041) 4.

The elective field should encompass:

• The thyroid bed (involved lobe or recurrent tumor bed) 4
• Regional nodal areas in the cervical neck including bilateral neck levels 4
• Upper mediastinum to the level described above 4

Cervical Lymph Node Levels

For clinically apparent or biopsy-proven nodal disease, therapeutic neck dissection of involved compartments should be performed surgically, with radiotherapy fields encompassing these areas postoperatively 3.

Central neck dissection (level VI) is indicated when lymph nodes are palpable or biopsy positive 3.

Lateral neck dissection (levels II-IV, consider level V) should be performed for lateral neck disease, sparing the spinal accessory nerve, internal jugular vein, and sternocleidomastoid muscle when possible 3.

Technical Planning Considerations

Simulation and Planning

• CT simulation with 3D treatment planning is strongly recommended for accurate target delineation 3
• IV and/or oral contrast may be used during CT simulation to aid in target localization, though iodinated contrast will delay subsequent radioiodine therapy 3
• Immobilization devices are strongly recommended for reproducibility of daily setup 3
• A lateral simulator film should be obtained to determine maximum spinal cord dose due to considerable variation in interplanar distance along the treatment volume 2

Dose Prescription and Fractionation

The recommended dose is 60-66 Gy for high-risk features including extracapsular disease or positive margins 3.

For patients with clear or microscopic positive margins:

• 45-50 Gy after complete resection 3
• 50-54 Gy after R1 (microscopic positive) resection 3

Conventional fractionation of 1.8-2.0 Gy per fraction is recommended 3.

A boost of 10 Gy to areas of likely residual disease is recommended when indicated 3.

Advanced Techniques

3D conformal radiotherapy or intensity-modulated radiation therapy (IMRT) targeted to the tumor bed is recommended 3.

IMRT may be appropriate in selected cases to reduce dose to normal structures such as heart and lungs, though attention must be given to low-to-moderate dose volumes 3.

Organ at Risk Constraints

Spinal Cord

The spinal cord dose should not exceed 45 Gy 3.

A mid-plane dose of 46 Gy in 23 daily fractions results in acceptable toxicity and avoids late spinal cord damage 2.

Maximum cord dose should be determined from lateral simulator films due to anatomic variation 2.

Lungs

Normal lung (>2 cm outside target volume) should not receive more than 40 Gy 3.

Limit the proportion of total lung receiving 20 Gy or more to 20% 3.

Limit the proportion of total lung receiving 10 Gy or more to 40% 3.

Other Structures

• At least 60% of liver should receive <30 Gy 3
• At least 2/3 of one kidney should receive <20 Gy 3
• No more than 1/3 of heart should receive 50 Gy, with efforts to minimize left ventricle doses 3

Common Pitfalls and Caveats

The most critical pitfall is using limited field radiotherapy that only covers the tumor bed and positive nodes, as this results in significantly worse locoregional control (40% vs. 89% at 5 years) compared to elective nodal irradiation 4.

Prophylactic irradiation of supraclavicular nodes is not recommended in thymic tumors 3, though this guideline is from thymic epithelial tumors and may not directly apply to thyroid cancer where supraclavicular coverage is typically included as part of the cervical nodal coverage 2.

The status of postoperative margins significantly influences outcomes, with 5-year locoregional control of 89.1% for clear/microscopic positive margins versus 69.2% for macroscopic residual disease 1. This emphasizes the importance of achieving macroscopic clearance surgically when possible.

Radiotherapy should commence within 3 months of surgery to optimize outcomes 3, though the preferred interval is 6 weeks or less 3.

Treatment interruptions or dose reductions for manageable acute toxicities should be avoided, with careful monitoring and aggressive supportive care preferred over treatment breaks 3.